Study of JNJ-75229414 a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against KLK2 for Metastatic Castration-Resistant Prostate Cancer
Enrolling By Invitation
18 years - 99 years
Male
Phase
1
60 participants needed
1 Location
Brief description of study
The purpose of this study is to determine recommended Phase 2 dose (RP2D) regimen(s) of JNJ-75229414 in Part 1 (Dose Escalation and to determine safety at the RP2D regimen(s) in Part 2 (Dose Expansion).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Prostate Cancer
-
Age: 18 years - 99 years
-
Gender: Male
Males, Age 18 or older , Metastatic CRPC (mCRPC) with histologic confirmation of adenocarcinoma.
Updated on
04 Aug 2024.
Study ID: 850439
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
